Clinical trial
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage…
NCT00065182 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00065182 |
|---|---|
| Title | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer |
| Official title | WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Topotecan/Docetaxel combination, Docetaxel |
| Enrollment | 399 |
| Start date | Aug 14, 2003 |
| Primary completion | Aug 30, 2007 |
| Completion | Aug 30, 2007 |
| First posted | Jul 18, 2003 |
| Last update posted | Jun 24, 2019 |
| Countries | Canada, Poland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: